Effect of Toll-like receptor 4 inhibitor on LPS-induced lung injury
Effect of Toll-like receptor 4 inhibitor on LPS-induced lung injury
复制标题
DOI:
10.1007/s00011-010-0195-3
复制
发表时间:
2010-04
影响因子:
6.7
通讯作者:
H. Seki;S. Tasaka;K. Fukunaga;Y. Shiraishi;Kiyoshi Moriyama;K. Miyamoto;Yasushi Nakano;N. Matsunaga;K. Takashima;Tatsumi Matsumoto;Masayuki Ii;A. Ishizaka;J. Takeda
中科院分区:
文献类型:
--
作者:
H. Seki;S. Tasaka;K. Fukunaga;Y. Shiraishi;Kiyoshi Moriyama;K. Miyamoto;Yasushi Nakano;N. Matsunaga;K. Takashima;Tatsumi Matsumoto;Masayuki Ii;A. Ishizaka;J. Takeda
Objective and designToll-like receptor 4 (TLR4) plays important roles in the recognition of lipopolysaccharide (LPS) and the activation of inflammatory cascade. In this study, we evaluated the effect of TAK-242, a selective TLR4 signal transduction inhibitor, on acute lung injury (ALI).Materials and methodsC57BL/6J mice were intravenously treated with TAK-242 15 min before the intratracheal administration of LPS or Pam3CSK4, a synthetic lipopeptide. Six hours after the challenge, bronchoalveolar lavage fluid was obtained for a differential cell count and the measurement of cytokine and myeloperoxidase levels. Lung permeability and nuclear factor-κB (NF-κB) DNA binding activity were also evaluated.ResultsTAK-242 effectively attenuated the neutrophil accumulation and activation in the lungs, the increase in lung permeability, production of inflammatory mediators, and NF-κB DNA-binding activity induced by the LPS challenge. In contrast, TAK-242 did not suppress inflammatory changes induced by Pam3CSK4.ConclusionTAK-242 may be a promising therapeutic agent for ALI, especially injuries associated with pneumonia caused by Gram-negative bacteria.